Orthopediatrics

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)

Retrieved on:

Thursday, April 4, 2024

ICSS, Patient, Orthopediatrics, Hospital, Rib, Cadaver, Surgeon, CME, Scoliosis, Adolescent idiopathic scoliosis, Elective surgery, Nursing

WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it will attend the 8th Annual International Children’s Spine Symposium (ICSS), which will take place April 5th and 6th in Denver, Colorado.

Key Points:

WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it will attend the 8th Annual International Children’s Spine Symposium (ICSS), which will take place April 5th and 6th in Denver, Colorado.
The meeting, put on by the Armstrong Children’s Orthopedic Alliance, offers a comprehensive program of lectures given by an outstanding, international faculty and cadaver labs centered on the cervical spine, lumbo-sacral junction, neuromonitoring, and various aspects of scoliosis.
We consider ICSS to be an interactive forum that allows us to engage with pediatric orthopedic fellows and attending surgeons and train on the latest technologies and surgical techniques.
The symposium is always well attended and receives great feedback from attendees, so I am looking forward to this being another productive event.”

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Wednesday, March 6, 2024

Acquisition, Deformity, International, Total, Infection, Investment, Marketing, Growth, Fixation (psychology), Response, Elective surgery, Orthopediatrics, Event, OPSB, Scoliosis, Webcast, Sport, Depreciation, Video game

Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.

Key Points:

Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.
The increase in revenue in the fourth quarter of 2023 was driven primarily by growth across Trauma and Deformity, Scoliosis, and OPSB.
In the fourth quarter of 2023, we realized an immaterial fair value adjustment benefit compared to a $0.5 million benefit for the fourth quarter of 2022.
Adjusted EBITDA for the fourth quarter of 2023 was $1.3 million as compared to a loss of $2.2 million for the fourth quarter of 2022.

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Retrieved on:

Monday, March 4, 2024

EOS, Rib, Elective surgery, Orthopediatrics, Adrenal insufficiency, Surgeon, Family, Scoliosis, Patient, Risk, Dentistry

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).

Key Points:

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).
The new addition to the RESPONSE™ family includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.
As an adjunct to the foundational RESPONSE™ Scoliosis System, the Rib and Pelvic system is compatible with 5.5/6.0 and 4.5/5.0 RESPONSE™ Systems, allowing surgeons to treat the entire spectrum of patients with scoliosis.
Greg Odle, President of the OrthoPediatrics’ Scoliosis Division echoed his excitement for the launch of this new system, saying “We are excited to enter the Early Onset Scoliosis treatment market with the RESPONSE™ Rib & Pelvic System.

OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana

Retrieved on:

Wednesday, February 28, 2024

KIDS, Culture, Commerce, Elective surgery, Orthopediatrics, Organization

WARSAW, Ind., Feb. 28, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was recently named one of the 2024 Best Places to Work in Indiana.

Key Points:

WARSAW, Ind., Feb. 28, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was recently named one of the 2024 Best Places to Work in Indiana.
This is the 8th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce.
OrthoPediatrics President & CEO David Bailey commented, “We are excited to be named one of the “Best Places to Work” in Indiana for an 8th time.
For more information on the Best Places to Work in Indiana program, visit:

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Retrieved on:

Thursday, February 22, 2024

Orthopediatrics, Event, Webcast, Elective surgery

WARSAW, Ind., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2023 financial results on Wednesday, March 6, 2024, after the market closes.

Key Points:

WARSAW, Ind., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2023 financial results on Wednesday, March 6, 2024, after the market closes.
OrthoPediatrics will host a conference call on Thursday, March 7, 2024, at 8:00 a.m.
ET to discuss the results.
The webcast will be available for replay for at least 90 days after the event.

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023

Retrieved on:

Monday, January 8, 2024

Acquisition, DF2, Orthopedic surgery, Elective surgery, Growth, Orthopediatrics, Pharmaceutical industry

During the fourth quarter of 2023 the Company helped nearly 20,000 children and since inception the Company has now helped over 710,000 children.

Key Points:

During the fourth quarter of 2023 the Company helped nearly 20,000 children and since inception the Company has now helped over 710,000 children.
Preliminary unaudited fourth quarter 2023 net revenue is expected to be $37.6 million, representing growth of 21% compared to $31.0 million in the fourth quarter of 2022.
Preliminary unaudited full year 2023 net revenue is expected to be $148.7 million, representing growth of 22% compared to $122.3 million in 2022.
The Company plans to release its fourth quarter and full year 2023 financial results and provide additional commentary on its financial outlook in March.

OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics

Retrieved on:

Monday, January 8, 2024

Plagiocephaly, Hospital, Nationwide, Caregiver, Acquisition, Scoliosis, Health, Brace, Boston brace, Elective surgery, Growth, Squadron Capital, Patient, DMO, Orthopediatrics

WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics (“Boston O&P”), a leader in pediatric orthotic management for over 50 years. Additionally, in advance of the acquisition, the Company closed a debt financing with MidCap Financial which provides up to $80 million of capital, through the combination of a term loan and revolving loan, replacing its prior unused $50 million line of credit.

Key Points:

WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics (“Boston O&P”), a leader in pediatric orthotic management for over 50 years.
Boston Orthotics & Prosthetics is a profitable company offering leading bracing, orthotic and prosthetic technology for the non-operative treatment of children whose lives have been impacted by scoliosis, plagiocephaly, and various neuromuscular disorders.
In advance of the acquisition, OrthoPediatrics entered into a new credit agreement with MidCap Financial, consisting of term loan and revolving loan.
In advance of the acquisition, OrthoPediatrics drew an initial $10 million from the term loan.

OrthoPediatrics Corp. to Host Educational and Networking Events at 19th Annual International Pediatric Orthopaedic Symposium (IPOS)

Retrieved on:

Monday, December 4, 2023

Emerald, Partnership, Surgeon, SCFE, Education, IPOS, Elective surgery, Orthopediatrics, OPSB

WARSAW, Ind., Dec. 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its increased support of the event as an Emerald-Level sponsor.

Key Points:

WARSAW, Ind., Dec. 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its increased support of the event as an Emerald-Level sponsor.
IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons.
Over 500 pediatric orthopedic surgeons are registered to attend the meeting from December 5-9, in Orlando, Florida.
OrthoPediatrics IPOS 2023 Events include:
Treatment Choices for SCFE – What to Choose and When?

OrthoPediatrics Corp. Reports Third Quarter 2023 Financial Results

Retrieved on:

Monday, November 6, 2023

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2023.

Key Points:

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2023.
Total revenue for the third quarter of 2023 was $40.0 million, a 14% increase compared to $35.0 million for the same period last year.
U.S. revenue for the third quarter of 2023 was $29.4 million, a 11% increase compared to $26.5 million for the same period last year, representing 73% of total revenue.
Adjusted EBITDA for the third quarter of 2023 was $3.6 million as compared to $1.9 million for the third quarter of 2022.

OrthoPediatrics Corp. Enters Distribution Agreement with Ora Medical

Retrieved on:

Monday, November 6, 2023

Child, Intermediary, Elective surgery, Organizational founder, Orthopediatrics, Organization, Transport, Partnership, Deformity, Levity, Trauma

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical’s gait trainer, The Levity, a device designed for children with walking difficulties.

Key Points:

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical’s gait trainer, The Levity, a device designed for children with walking difficulties.
This allows the child to interact with the world using their arms, unlocking tons of possibilities.
Joe Hauser, President of Trauma and Deformity Correction at OrthoPediatrics, added, “Our new partnership with the team at Ora Medical is an exciting step in our non-surgical business.
Their established market presence and expertise will facilitate the distribution of our device, furthering our mission to improve the mobility of children globally.”